ArticleFrontiers in oncology2025
Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic cancer is a highly aggressive malignancy with a 6% five-year survival rate. CHRDL1, a BMP4 antagonist, has tumor-suppressive effects in breast and gastric cancers, but its role in pancreatic cancer is unclear. This study explores CHRDL1's function and mechanism in pancreatic cancer. Methods: Stably transfected pancreatic cancer cell lines (PANC-1, SW1990) with lentivirus-mediated CHRDL1 overexpression were established to assess effects on cell proliferation, migration, and adhesion. Recombinant BMP4 treatment validated CHRDL1's antagonism. Additionally, the TCGA database, immunohistochemistry, and RT-qPCR in both cell lines and patient tissues confirmed CHRDL1 expression. In vivo experiments were also conducted to observe the effect of CHRDL1 overexpression on pulmonary metastases. Results: CHRDL1 was downregulated in pancreatic cancer, correlating with poor prognosis. Overexpression inhibited cell migration and adhesion (without affecting proliferation), reduced SMAD1/5/9 phosphorylation and RUNX2 expression, and counteracted BMP4-induced malignant behaviors. Discussion: CHRDL1 exerts tumor-suppressive effects in pancreatic cancer by inhibiting the BMP4/SMAD pathway, reducing migration, invasion, and metastasis. These findings clarify CHRDL1's role, enhance understanding of pancreatic cancer mechanisms, and may offer diagnostic and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.